EP3833683A4 - Polypeptid-integrin-antagonisten - Google Patents
Polypeptid-integrin-antagonisten Download PDFInfo
- Publication number
- EP3833683A4 EP3833683A4 EP19848229.1A EP19848229A EP3833683A4 EP 3833683 A4 EP3833683 A4 EP 3833683A4 EP 19848229 A EP19848229 A EP 19848229A EP 3833683 A4 EP3833683 A4 EP 3833683A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- integrin antagonists
- integrin
- antagonists
- polypeptide integrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005557 antagonist Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862715860P | 2018-08-08 | 2018-08-08 | |
US201862757126P | 2018-11-07 | 2018-11-07 | |
US201862786804P | 2018-12-31 | 2018-12-31 | |
PCT/US2019/045762 WO2020033731A1 (en) | 2018-08-08 | 2019-08-08 | Polypeptide integrin antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3833683A1 EP3833683A1 (de) | 2021-06-16 |
EP3833683A4 true EP3833683A4 (de) | 2022-09-28 |
Family
ID=69415156
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19847358.9A Pending EP3860977A4 (de) | 2018-08-08 | 2019-08-08 | Integrinantagonisten |
EP19848229.1A Pending EP3833683A4 (de) | 2018-08-08 | 2019-08-08 | Polypeptid-integrin-antagonisten |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19847358.9A Pending EP3860977A4 (de) | 2018-08-08 | 2019-08-08 | Integrinantagonisten |
Country Status (5)
Country | Link |
---|---|
US (3) | US11643393B2 (de) |
EP (2) | EP3860977A4 (de) |
AU (2) | AU2019316562B2 (de) |
CA (2) | CA3112193A1 (de) |
WO (2) | WO2020033724A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10533044B2 (en) * | 2014-01-06 | 2020-01-14 | The General Hospital Corporation | Integrin Antagonists |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
SG11202103484RA (en) | 2018-10-30 | 2021-05-28 | Gilead Sciences Inc | Quinoline derivatives as alpha4beta7 integrin inhibitors |
JP7189368B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリンの阻害のための化合物 |
CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
EP4178963A1 (de) * | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c!pyrazol-2-yl!indazolderivate und verwandte verbindungen als modulatoren zum spleissen von nukleinsäuren und zur behandlung proliferativer erkrankungen |
US20240209034A1 (en) * | 2021-04-12 | 2024-06-27 | University Of Washington | Engineering peptides for a a vb6 integrin binding and related methods of use and synthesis |
CA3228660A1 (en) * | 2021-08-10 | 2023-02-16 | Texas Heart Institute | Aminoaryl-integrin agonists compounds |
WO2023133229A2 (en) * | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013185027A2 (en) * | 2012-06-07 | 2013-12-12 | Dcb-Usa Llc | Modified fibronectin fragments or variants and uses thereof |
WO2015103643A2 (en) * | 2014-01-06 | 2015-07-09 | The General Hospital Corporation | Integrin antagonists |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645815A (en) * | 1991-02-08 | 1997-07-08 | Diatide, Inc. | Radiolabled compounds for thrombus imaging |
US5217994A (en) * | 1991-08-09 | 1993-06-08 | Merck & Co., Inc. | Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives |
EP1054871A2 (de) | 1998-04-01 | 2000-11-29 | Du Pont Pharmaceuticals Company | Pyrimidine und triazine als integrinantagonisten |
CN107542013B (zh) * | 2016-06-27 | 2019-06-21 | 一路行(北京)科技有限公司 | 一种臂结构及采用臂结构的道床线路施工与维护装置 |
MX2019000043A (es) | 2016-07-05 | 2019-07-04 | Univ Rockefeller | Antagonistas de integrina de tetrahidronaftiridinpentanamida. |
-
2019
- 2019-08-08 US US17/266,336 patent/US11643393B2/en active Active
- 2019-08-08 EP EP19847358.9A patent/EP3860977A4/de active Pending
- 2019-08-08 WO PCT/US2019/045752 patent/WO2020033724A1/en unknown
- 2019-08-08 EP EP19848229.1A patent/EP3833683A4/de active Pending
- 2019-08-08 AU AU2019316562A patent/AU2019316562B2/en active Active
- 2019-08-08 US US17/266,339 patent/US11685717B2/en active Active
- 2019-08-08 CA CA3112193A patent/CA3112193A1/en active Pending
- 2019-08-08 AU AU2019318538A patent/AU2019318538A1/en active Pending
- 2019-08-08 CA CA3112523A patent/CA3112523A1/en active Pending
- 2019-08-08 WO PCT/US2019/045762 patent/WO2020033731A1/en unknown
-
2023
- 2023-05-12 US US18/317,017 patent/US20240076268A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013185027A2 (en) * | 2012-06-07 | 2013-12-12 | Dcb-Usa Llc | Modified fibronectin fragments or variants and uses thereof |
WO2015103643A2 (en) * | 2014-01-06 | 2015-07-09 | The General Hospital Corporation | Integrin antagonists |
Non-Patent Citations (7)
Title |
---|
DATABASE Geneseq [online] 10 September 2015 (2015-09-10), "Human fibronectin type III domain protein fragment, SEQ ID 71.", XP002807324, retrieved from EBI accession no. GSP:BCC05345 Database accession no. BCC05345 * |
DATABASE Geneseq [online] 10 September 2015 (2015-09-10), "Human mutant fibronectin type III domain protein fragment, SEQ ID 72.", XP002807323, retrieved from EBI accession no. GSP:BCC05346 Database accession no. BCC05346 * |
DATABASE Geneseq [online] 13 February 2014 (2014-02-13), "Human FNIII 10 mutant protein (CX8C), SEQ:50.", XP002807325, retrieved from EBI accession no. GSP:BBA87860 Database accession no. BBA87860 * |
ESTEVEZ BRIAN ET AL: "Targeting Integrin and Integrin Signaling in Treating Thrombosis", TRANSLATIONAL SCIENCES, vol. 35, no. 1, 1 January 2015 (2015-01-01), pages 24 - 29, XP055950969, ISSN: 1079-5642, DOI: 10.1161/ATVBAHA.114.303411 * |
RICHARDS J ET AL: "Engineered Fibronectin Type III Domain with a RGDWXE Sequence Binds with Enhanced Affinity and Specificity to Human @av@b3 Integrin", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 326, no. 5, 7 March 2003 (2003-03-07), pages 1475 - 1488, XP004454119, ISSN: 0022-2836, DOI: 10.1016/S0022-2836(03)00082-2 * |
See also references of WO2020033731A1 * |
VAN AGTHOVEN JOHANNES F ET AL: "Structural basis for pure antagonism of integrin [alpha]V[beta]3 by a high-affinity form of fibronectin", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 21, no. 4, 23 March 2014 (2014-03-23), New York, pages 1 - 20, XP055920470, ISSN: 1545-9993, Retrieved from the Internet <URL:http://www.nature.com/articles/nsmb.2797> DOI: 10.1038/nsmb.2797 * |
Also Published As
Publication number | Publication date |
---|---|
US11685717B2 (en) | 2023-06-27 |
AU2019316562A1 (en) | 2021-03-25 |
US20220356217A1 (en) | 2022-11-10 |
EP3860977A1 (de) | 2021-08-11 |
CA3112523A1 (en) | 2020-02-13 |
US20220081398A1 (en) | 2022-03-17 |
CA3112193A1 (en) | 2020-02-13 |
WO2020033731A1 (en) | 2020-02-13 |
AU2019318538A1 (en) | 2021-03-25 |
EP3860977A4 (de) | 2023-02-22 |
AU2019316562B2 (en) | 2024-03-28 |
WO2020033724A1 (en) | 2020-02-13 |
US11643393B2 (en) | 2023-05-09 |
US20240076268A1 (en) | 2024-03-07 |
EP3833683A1 (de) | 2021-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3833683A4 (de) | Polypeptid-integrin-antagonisten | |
EP3565839A4 (de) | Checkpoint-regulatorantagonisten | |
EP3439658A4 (de) | Lösliche c5ar-antagonisten | |
EP3755311A4 (de) | Indanamine als pd-l1-antagonisten | |
EP3481814A4 (de) | Tetrahydronaphthyridinpentanamid-integrin-antagonisten | |
EP3143037A4 (de) | Alpha4beta7-integrin-thioether-peptidantagonisten | |
ZA202101406B (en) | Integrin antagonists | |
GB201719557D0 (en) | Polypeptide | |
GB201905552D0 (en) | Antagonists | |
EP3562826A4 (de) | Integrinantagonisten | |
IL292692A (en) | mrgprx2 antagonists and their uses | |
EP3813861A4 (de) | Heparin-assoziierte polypeptide und deren verwendung | |
EP3768720A4 (de) | Neuartiges anti-lag-3-antikörper-polypeptid | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
EP3747784A4 (de) | Delaminierungsbehälter | |
EP3894441A4 (de) | Rank-antagonisten und deren verwendungen | |
EP3858868A4 (de) | Polypeptidzusammensetzung | |
EP3802565A4 (de) | Polypeptide | |
EP3816186A4 (de) | Pd-l1-bindende polypeptide und verwendung davon | |
EP3653063A4 (de) | Peptid | |
AU2019350356A1 (en) | Arginase1 polypeptides | |
EP3851448A4 (de) | Antierythropoietinrezeptor-peptid | |
GB201815629D0 (en) | Antagonists | |
EP3725884A4 (de) | Zellmembranpermeable peptide | |
EP3744651A4 (de) | Delaminierungsbehälter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210305 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE GENERAL HOSPITAL CORPORATION |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 49/00 20060101ALI20220818BHEP Ipc: A61P 1/16 20060101ALI20220818BHEP Ipc: C07K 7/64 20060101ALI20220818BHEP Ipc: C07K 14/705 20060101ALI20220818BHEP Ipc: C07K 14/78 20060101AFI20220818BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220825 |